Hexima is undertaking an externally funded human disease program. The program is still considered to be in the discovery stage, but the Company is encouraged by its initial findings. In November 2009, the Company announced that it intended to undertake the next stage of research, which will determine whether any of the molecules of interest progress into clinical trials over the next 2–3 years.